Analysis of Seasonal Influenza Outbreak Trends in the United States from 2005-2015 by Roosa, Kimberlyn
Georgia State University
ScholarWorks @ Georgia State University
Public Health Theses School of Public Health
Spring 5-12-2017
Analysis of Seasonal Influenza Outbreak Trends in
the United States from 2005-2015
Kimberlyn Roosa
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Public Health Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.
Recommended Citation
Roosa, Kimberlyn, "Analysis of Seasonal Influenza Outbreak Trends in the United States from 2005-2015." Thesis, Georgia State
University, 2017.
https://scholarworks.gsu.edu/iph_theses/531
1 
 
 
Analysis of Seasonal Influenza Outbreak Trends in the United 
States from 2005-2015 
 
 
by 
 
Kimberlyn Marie Roosa 
 
B.S., University of South Carolina 
 
 
 
 
 
A Thesis Submitted to the Graduate Faculty 
of Georgia State University in Partial Fulfillment 
of the 
Requirements for the Degree 
 
MASTER OF PUBLIC HEALTH 
 
 
ATLANTA, GEORGIA 
30303 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
Analysis of Seasonal Influenza Outbreak Trends in the United 
States from 2005-2015 
 
 
by  
 
Kimberlyn M. Roosa 
 
 
 
 
 
 
Approved:  
 
 
 
Gerardo Chowell, PhD 
Committee Chair  
 
 
 
Matthew Magee, PhD, MPH 
Committee Member  
 
 
 
April 24, 2017 
 
 
 
  
 
 
 
 
 
 
 
3 
 
Author’s Statement Page  
 
 
In presenting this thesis as a partial fulfillment of the requirements for an advanced 
degree from Georgia State University, I agree that the Library of the University shall make it 
available for inspection and circulation in accordance with its regulations governing materials of 
this type. I agree that permission to quote from, to copy from, or to publish this thesis may be 
granted by the author or, in his/her absence, by the professor under whose direction it was 
written, or in his/her absence, by the Associate Dean, School of Public Health. Such quoting, 
copying, or publishing must be solely for scholarly purposes and will not involve potential 
financial gain. It is understood that any copying from or publication of this dissertation which 
involves potential financial gain will not be allowed without written permission of the author.  
 
Kimberlyn Marie Roosa 
 
 
 
 
 
 
 
 
 
  
4 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES…………………………………………………………………………... 5 
ABSTRACT.............................................................................................................................. 6 
INTRODUCTION..................................................................................................................... 7 
 
LITERATURE REVIEW.......................................................................................................... 8 
 
MANUSCRIPT 
     Introduction ………………………………………………………………………………. 14 
     Methods …………………………………………………..………………………………. 16 
     Results …………................................................................................................................. 20 
     Discussion............................................................................................................................ 22 
 
REFERENCES.......................................................................................................................... 26 
FIGURES…………………………………………………………………………………….. 28 
 
 
  
5 
 
 
List of Figures 
 
 
Figure 1. Map of Health and Human Services Regions  
Figure 2. Peak week over time (by year) per HHS Region 
Figure 3. Peak timing (week) by Health and Human Services Region (p=0.8541) 
Figure 4. Maximum ILI total (peak size) over time (year) per HHS region (p=0.012) 
Figure 5. Correlation of peak size by peak week (p=0.0005) 
Figure 6. Month in which the peak of the outbreak occurs by dominant subtype circulating 
(p=0.0396) 
Figure 7. Peak timing (week) by dominant subtype circulating (p=0.0337) 
Figure 8. Peak influenza-like illness total by dominant subtype circulating (p=0.1984) 
Figure 9. Peak influenza-like illness total by month in which the peak occurs (p=0.0494) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Analysis of Seasonal Influenza Outbreak Trends in the United States from 2005-2015 
 
By 
 
Kimberlyn Marie Roosa 
 
April 24, 2017 
 
 
ABSTRACT 
 
 
 
Background: 
Seasonal influenza epidemics occur annually in the United States (U.S.) and result in lost 
workforce productivity, strained healthcare services, and an annual economic burden of $11 
billion. While the U.S. has a comprehensive surveillance system, and the Centers for Disease 
Control and Prevention (CDC) publishes weekly updates on the outlook of seasonal influenza 
activity (FluView), there is a lack of literature analyzing seasonal influenza peak trends across 
and within regions of the country over multiple flu seasons. This study aimed to identify trends 
over time (2005-2015) in the timing and size of seasonal flu outbreak peaks, both across and 
within Health and Human Services regions.  
Methods: 
Secondary data analysis was conducted on U.S. national influenza surveillance data compiled 
and provided by the CDC. The study includes all persons in the United States (all 50 states, 
District of Columbia, Puerto Rico, and the U.S. Virgin Islands) who sought healthcare for 
influenza-like illness (ILI) during the 2005-06 flu season through the 2014-15 season. Trends 
over time in peak timing and size were assessed overall (across all HHS regions) and within 
regions. The effect of the dominant subtype of influenza virus circulating on peak timing and 
size was also assessed.  
Results: 
Trends in seasonal influenza outbreaks revealed peaks that occurred earlier over time (p<0.0001) 
and increased in size over time (p=0.0012). The median peak week did not vary significantly by 
region (p=0.8541). Also, peak week and peak size were negatively correlated showing that 
earlier epidemics result in higher ILI rates. The timing of the epidemic differed depending on the 
dominant subtype circulating (p=0.0337) with subtype 2009 H1N1peaks occurring 3.5 weeks 
earlier than H1 peaks; however, subtype did not have a significant effect on the size of the 
epidemic peak (p=0.1984). 
Conclusion: 
A significant decrease in peak week and a significant increase in peak size were observed over 
time, revealing a trend of earlier and more intense seasonal flu peaks. Since earlier epidemics are 
correlated with higher rates of ILI, anticipating earlier seasonal peaks highlights the importance 
of vaccination and other flu prevention strategies being utilized early in the flu season. 
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Introduction 
 
Influenza, commonly known as the ‘flu’, is a highly pathogenic disease caused by 
infection with an influenza virus, typically spread through contact with contaminated droplets in 
the air [1, 2]. The symptoms of influenza (fever, cough, headache, muscle and joint pain, sore 
throat, and runny nose) are common among other illnesses including meningitis, tuberculosis, 
and hepatitis A, but the seasonality of flu epidemics distinguishes influenza from these other 
clinically similar diseases [3]. Seasonal flu outbreaks are the results of small changes in strains of 
the virus already circulating among humans; these viruses typically result in epidemics with high 
number of infected persons, a generally low death rate, and few complications compared to 
epidemics of clinically similar diseases [3]. In temperate areas, large and intense outbreaks occur 
in winter months, followed by periods with little to no flu activity in warmer months [4]. In the 
United States (U.S.), seasonal flu epidemics cause 5-20% of the population to become ill with 
influenza each year, resulting in lost workforce productivity, strained healthcare services, and an 
annual economic burden of $11 billion [1, 4].   
The purpose of this study was to identify trends in timing and size of seasonal influenza 
epidemic peaks over a 10 year period (2005-2015) in the United States. National data was 
assessed as well as regional data by Health and Human Services (HHS) region. Peak timing was 
analyzed by HHS region to identify any variation in epidemic peak timing across regions of the 
United States. The dominant subtype (type A) of influenza virus circulating at epidemic peak 
was compared with peak timing and size to determine the effect of dominant subtype on these 
peak characteristics.  
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Literature Review 
Overview of Influenza: 
 Influenza, or the ‘flu’, is a highly pathogenic disease caused by infection with an 
influenza virus. There are three types of influenza viruses: influenza type A infects humans and 
various animals, type B circulates only within humans, and type C can infect humans and pigs, 
but infections are typically mild and sporadic [3, 5, 6]. Influenza type A viruses are further 
categorized into subtypes distinguished by antigenic properties (refers to how the virus alters its 
surface proteins to evade a host immune response) of its surface glycoproteins, and type B 
viruses are divided into two main groups or lineages [3, 5, 6]. Despite common nomenclature of 
type A viruses circulating among humans and animals (H1N1: swine; H3N2: avian), the viruses 
are distinct; a human can be infected with an animal flu virus through direct contact with an 
infected animal, but the virus is not likely to spread far within a human population [5, 6]. While 
type A and type B viruses are responsible for seasonal flu epidemics, only type A viruses are 
known to have caused pandemics [1, 5, 6].  
 
Transmission and Risk Factors: 
 When a person infected with influenza coughs, sneezes, or talks, droplets containing 
viruses are dispersed into the air and can spread up to six feet from the host [1, 2]. Droplets can 
land in mouths or noses or possibly even breathed into the lungs; influenza can also be spread by 
touching hands or other surfaces that are contaminated with the virus and then touching the nose 
or mouth [1, 2]. Those infected with influenza can transmit the disease up to one day before 
symptoms appear and remain infectious for five to seven days after becoming sick [2].  
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 Influenza can affect all populations, but those at an increased risk for complications 
include: pregnant women, young children (aged 6-59 months), elderly persons, and those with 
weakened immune systems or underlying conditions [1, 6]. Underlying conditions that may 
increase the risk for complications include: HIV/AIDS, asthma, chronic heart or lung diseases, 
neurological or neurodevelopmental conditions, blood disorders, diabetes, kidney or liver 
disease, extreme obesity (BMI > 40), and metabolic disorders [1, 6, 7]. Influenza also spreads 
easily and rapidly in crowded areas like schools and nursing homes [1]. In addition, healthcare 
workers are at an increased risk, as their risk of exposure is high [7].  
 
Symptoms, Complications, and Burden:  
 Influenza is characterized by the sudden onset of fever, cough, headache, muscle and 
joint pain, severe malaise, sore throat, and runny nose [1]. Most people recover from the 
symptoms within a week without medical attention; however, influenza can cause severe 
complications or death, especially in the high-risk populations previously mentioned [7]. Sinus 
and ear infections are moderate complications of influenza. More severe complications include: 
pneumonia, inflammation of the heart, brain, or muscle tissue, multi-organ failure, and sepsis [8]. 
Influenza can also worsen previous conditions like asthma and chronic heart disease [8].  
 In the United States, between 5-20% of the population becomes sick with influenza each 
year, and on average, 36,000 people die from flu-related complications [4]. Influenza epidemics 
can also take an economic toll on the country due to increased absenteeism in schools and 
workplaces, lost workforce productivity, and strained healthcare services [1]. Clinics and 
hospitals can be overwhelmed by the high volumes of patients during a flu epidemic. Overall, the 
economic burden of influenza in the United States is estimated at $19 billion annually [4].  
10 
 
Treatment and Vaccination:  
 Only two classes of agents have licensed products for treatment of the flu: influenza 
neuraminidase (NA) inhibitors and M2 proton channel blockers [9]. Viral resistance to the M2 
blockers is frequently reported, which limits the effectiveness of the treatment, and only NA 
inhibitors are active against the currently circulating seasonal influenza viruses [1, 9]. The World 
Health Organization (WHO) recommends NA inhibitors as first-line treatment [1]. While the 
treatment options are limited, these antiviral drugs (available in some countries) can lesson 
symptoms, shorten sick time, and reduce the risk of severe complications and death, and should 
be administered ideally within 48 hours of symptom onset [1].  
 Vaccination is the most effective way to prevent disease from influenza; vaccines are safe 
and effective and have been used for over 60 years [1]. Vaccines are especially important for 
those populations at increased risk for flu complications and for people who live with or care for 
these high-risk persons [1, 10]. While flu vaccines are most effective when well-matched with 
the circulating viruses, among healthy adults, vaccination provides protection even when the 
viruses are not exactly matched [1]. 
 The United States Centers for Disease Control and Prevention (CDC) provides 
vaccination recommendations each year regarding the strain, timing, and type of vaccine 
administered. On February 24, 2010, the CDC’s Advisory Committee on Immunization Practices 
voted for “universal” flu vaccination in the United States to expand flu protection, so the CDC 
recommends that everyone six months or older should be vaccinated each flu season [10].  The 
CDC currently recommends the inactivated influenza vaccine (IIV) for all ages (over 6 months) 
or the recombinant influenza vaccine (RIV) for ages 18-49 years [11]. IIV is an intramuscular or 
intradermal injection of an inactive flu virus, and RIV is a new option (licensed January 2013) 
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that does not contain a flu virus [11, 12]. The live attenuated influenza vaccine (LAIV) is a nasal 
spray option (2-49 years), but the CDC is not recommending this option for the 2016-17 flu 
season due to the decreased effectiveness of the vaccine [11]. It is also important to note that it 
takes two weeks after vaccination for antibodies to develop and provide protection [12]. 
 
Nonpharmaceutical Interventions: 
 Nonpharmaceutical interventions (NPIs) are actions that individuals and communities can 
take to slow the spread of infectious diseases like influenza. In 2007, the CDC collaborated with 
other federal agencies, educational institutions, businesses, healthcare providers, and private 
enterprises to develop an interim planning guide on the use of NPIs [13]. NPIs are some of the 
best ways of controlling influenza epidemics when vaccines have yet to be created and provide 
an extra layer of protection when vaccination is available [14]. 
 Voluntary home quarantine, hand hygiene, face masks, and covering mouth with a tissue 
while coughing or sneezing are examples of personal NPIs [1, 13]. A study conducted in 2010 
found that when compared with a non-masked control group, the use of face masks and hand 
hygiene significantly reduced the influenza-like illness (ILI) rates [13].  Surface cleaning is an 
environmental NPI that can be utilized to decrease risk of disease [14].  
 Community NPIs are used to slow the spread of disease once an epidemic is identified. 
Social distancing (increasing the distance between people) and closures are used in priority 
settings, such as child care centers, schools, workplaces, places of worship, events, concerts, 
meetings, and other events where people gather. While these are difficult to plan and execute, 
they can be the most effective ways to protect the community from the impact of the pandemic 
[14].  
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Seasonal vs. Pandemic Influenza: 
 Certain influenza viruses (within type A and B) circulate seasonally and cause disease in 
humans each year. In temperate climates, seasonal epidemics tend to occur in the winter months 
[6]. In tropical regions, flu seasonality is less obvious and epidemics occur irregularly throughout 
the year [1]. These seasonal viruses evolve continuously through a process called ‘antigenic 
drift’ which results in small changes in genes over time as the virus replicates. This process 
produces viruses that are closely-related, so immune systems exposed to a similar virus can 
usually recognize the virus and respond (cross-protection); however, these small changes can 
accumulate over time, so immune systems may not recognize it [15]. For this reason, people can 
be infected with influenza multiple times throughout their lives, and components of seasonal flu 
vaccines must be reviewed frequently and updated periodically to ensure effectiveness [6, 15].  
 ‘Antigenic shift’ is an abrupt, major change in an influenza type A virus that results in 
new proteins in flu viruses that infect humans [15]. These pandemics are typically zoonotic 
influenza viruses that adapt or acquire certain genes from human viruses that allow them to 
spread easily amongst a human population with little previous immunity, so the virus rapidly 
transmits and causes large outbreaks outside of the normal flu season [6]. Ongoing circulation of 
certain bird-flu types (A(H5), A(H7N9)) is a public health concern, as these commonly cause 
severe disease in humans and have the potential to mutate and become more transmissible [5].  
 
Surveillance in the United States: 
 Surveillance of influenza or ILI provides useful information concerning future effects of 
seasonal and pandemic influenza. The data can contribute to decisions regarding flu strains 
selected for annual vaccine production, use of antiviral treatment, and groups to recommend the 
13 
 
annual vaccine [16]. The CDC has a multi-component influenza surveillance system with the 
following goals: 1. Determine location and timing of influenza activity; 2. Determine which 
viruses are circulating; 3. Detect changes in circulating viruses; 4. Track influenza-related 
illness; 5. Measure impact on hospitalizations and deaths [17]. This comprehensive system has 
eight different surveillance components in five categories that cover all 50 states, District of 
Columbia (DC), Puerto Rico, and the U.S. Virgin Islands.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
Manuscript 
 
Introduction 
 Influenza, commonly known as the ‘flu’, is a highly pathogenic disease caused by 
infection with an influenza virus, typically spread through contact with contaminated droplets in 
the air [1, 2]. There are three types of influenza viruses: influenza type A infects humans and 
various animals, type B circulates only within humans, and type C can infect humans and pigs, 
but infections are typically mild and sporadic [3, 5, 6]. Pandemics of influenza occur when a 
virus strain not previously seen in humans emerges; the majority of persons do not have 
immunity, so the new strain has the ability to spread rapidly and easily through a human 
population [1]. Seasonal influenza outbreaks are the results of small changes in strains of the 
virus already circulating among humans [1]. While only type A is known to have caused 
pandemics, both type A and type B viruses circulate during the periodic, or seasonal, epidemics 
of influenza [1, 5, 6]. Once a pandemic virus has been established, it can begin circulating as a 
seasonal flu virus, for example: 2009 A(H1N1) [1]. 
The symptoms of influenza (fever, cough, headache, muscle and joint pain, sore throat, 
and runny nose) are common among other illnesses including meningitis, tuberculosis, and 
hepatitis A [3]. While influenza is clinically similar to other diseases, the characteristics of 
seasonal flu outbreaks are distinct. Seasonal flu viruses typically result in epidemics with high 
number of infected persons, a generally low death rate, and few complications compared to 
epidemics of clinically similar diseases [3]. In temperate areas, large and intense outbreaks occur 
in winter months, followed by periods with little to no flu activity in warmer months [4]. In the 
United States (U.S.), seasonal flu epidemics cause 5-20% of the population to become ill with 
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the flu each year, resulting in lost workforce productivity, strained healthcare services, and an 
annual economic burden of $11 billion [1, 4].  
 The United States Centers for Disease Control and Prevention (CDC) gathers influenza-
related data from public health and clinical laboratories in all 50 states, District of Columbia, 
Puerto Rico, and the U.S. Virgin Islands through a comprehensive surveillance system. The CDC 
compiles the data and disseminates the information through weekly influenza surveillance 
reports, or FluView [17]. Within the FluView reports, the CDC provides information regarding 
characteristics and trends of the current seasonal flu epidemic; however, they do not assess how 
these trends have changed over multiple flu seasons [17]. Since FluView data is reported with a 
lag, it is not ideal for in-season predictions, and so various other data sources using online 
information are being compared to FluView to assess correlation. Some of these sources include: 
Google Flu Trends, Twitter, and Wikipedia. The lag in FluView data was not an issue for this 
study, as we were assessing trends over multiple flu seasons.   
The purpose of this study was to identify trends in timing and size of seasonal influenza 
epidemic peaks over a 10 year period (2005-2015) in the United States. National data were 
assessed as well as regional data by Health and Human Services (HHS) region. Peak timing was 
analyzed by HHS region to identify any variation in epidemic peak timing across regions of the 
United States. The dominant subtype (type A) of influenza virus circulating at epidemic peak 
was compared with peak timing and size to determine the effect of dominant subtype on these 
peak characteristics.  
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Methods 
Study Design 
 This study was a cross-sectional, secondary analysis of existing U.S. national influenza 
surveillance data provided by the CDC (2005-2015).  
Setting and Participants 
 The study population for this analysis was the U.S. population (all 50 states, DC, Puerto 
Rico, and the U.S. Virgin Islands) who sought healthcare for ILI for flu seasons 2005-06 through 
2014-15. Data were assessed on a national level as well as broken down by the ten Health and 
Human Services (HHS) regions (Figure 1).  
 The 2009-10 flu season was excluded from analysis as the exceptionally large peaks and 
early timing were due to the H1N1 pandemic, which occurred outside the regular flu season. 
Since the 2009 H1N1 strain was a new strain, not previously seen in humans, the 2009 epidemic 
was classified as pandemic rather than seasonal. Also, using Grubb’s Test, it was found that the 
peak size in the 2009-10 season was an outlier in half of the regions (HHS regions 1, 5, 7, 8, 10) 
and peak timing was an outlier in four of the regions (1, 6, 7, 10), so this season was excluded 
from analysis. 
Variables 
 For each region, peak size was defined as the maximum ILI weekly total per flu season, 
and peak timing was defined as the week of the flu season that this maximum occurred. The 
CDC’s definition of flu season was used: Week 40 through Week 39 of the following year. The 
peak week variable was coded as Week 1 of the flu season equating to Week 40 of the calendar 
year. The peak weeks were then categorized by the month in which they occurred (based on the 
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first day of the week – Sunday) to create the peak month variable. Both peak week and peak 
month were used. These variables were obtained from ILINet data. 
 For each region, data on the subtype (type A) circulating was recorded per peak week. 
The subtype with the highest percentage of positive tests was recorded as the dominant subtype 
circulating. Subtypes H1, H3, and 2009 H1N1 were included. This data was obtained from the 
virologic surveillance system.  
Data Source  
FluView is a weekly influenza surveillance report that contains information on year-
round influenza activity in the United States. The Epidemiology and Prevention Branch in the 
Influenza division at the CDC collects, compiles, and analyzes the information provided by the 
collaborative surveillance system conducted by the CDC and its partners in state, local, and 
territorial health departments, public health and clinical laboratories, vital statistics offices, 
healthcare providers, clinics, and emergency departments. The comprehensive system contains 
five categories of influenza surveillance; information from virologic surveillance and outpatient 
illness surveillance categories were used for this analysis. [17] 
 The virologic surveillance category contains data from approximately 100 public health 
and over 300 clinical laboratories spanning all 50 states, Puerto Rico, and the District of 
Columbia (DC). The laboratories perform subtyping tests on respiratory samples from patients 
exhibiting ILI and report data regarding influenza virus type and subtype through either the U.S. 
WHO Collaborating Laboratories System or the National Respiratory and Enteric Virus 
Surveillance System (NREVSS). Influenza subtype data from this system were utilized for this 
analysis. [17] 
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 The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) consists of over 
2,800 enrolled outpatient healthcare providers in all 50 states, Puerto Rico, DC, and the U.S. 
Virgin Islands that report information on patient visits for influenza-like illness (ILI). For this 
surveillance system, ILI is defined as having a fever of 100° Fahrenheit (F) or higher, and cough 
and/or sore throat with no other known cause besides influenza. Data on reported number of ILI 
visits were used for this analysis. [17] 
Statistical Methods 
 Microsoft Excel was used to organize data. SAS 9.4 was used for recoding variables and 
performing statistical tests.  An alpha level of 0.05 was used for all statistical tests. 
 The Shapiro-Wilk test for normality was used to determine if variables followed a normal 
distribution. Variables were tested across regions and within regions. Histograms and QQ-plots 
were also examined, as the sample size within regions (N=9) was small and could result in a non-
significant result due to lack of statistical power. These tests and/or visuals revealed non-
normality across all of the variables. 
 The following comparisons were tested across regions using the Kruskal-Wallis test 
(npar1way procedure in SAS): peak size by month, peak size by dominant subtype, peak week 
by subtype, and peak week by region (dependent by independent variable). Peak size was not 
tested across HHS regions, as there is high variation in population size, baseline ILI percentage, 
and other population factors that could affect the number of ILI visits, so the difference in 
median peak sizes across HHS regions would not provide any useful information for this study.
 Dunn’s test was used as a post-hoc test multiple comparisons test for associations that 
revealed statistical significance in the Kruskal-Wallis test. This was done using a Dunn macro in 
SAS provided by Cornell University [18]. 
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 The association between peak month and dominant subtype was assessed using Fisher’s 
exact test of independence (proc freq procedure with Fisher option in SAS).  
 The following correlations were tested (proc corr with Spearman option in SAS) both 
across regions and within regions: peak size and flu season, peak size and peak week, and peak 
week and flu season.  
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Results  
 This analysis contained data on 90 seasonal influenza epidemic peaks: 9 flu seasons and 
10 HHS regions. Among the 90 peaks, 38 (42.22%) occurred in February, 24 (26.67%) in 
January, 15 (16.67%) in December, 12 (13.33%) in March, and 1 (1.11%) in April. H3 was the 
dominant subtype circulating for 57 (63.33%) of the seasonal flu peaks, H1 for 18 (20.00%), and 
the 2009 H1N1 subtype for 15 (16.67%).  
 Trends in epidemic peak timing (peak week) reveal that seasonal influenza outbreak 
peaks have been occurring earlier over time (p<0.0001, Figure 2). While all HHS regions 
followed the trend, Regions 2, 9, and 10 showed little correlation to the downward trend in peak 
week. Peak timing was consistent across regions with a median peak week range of 18-21 weeks 
(p=0.8541, Figure 3).  
Seasonal epidemic peaks also revealed an upward trend in size of peaks over time across 
all regions (p=0.012, Figure 4). Increasing peak size over time was less of a trend in Region 4. It 
was observed that the earlier the epidemic peak occurred, the larger the peak size was (p=0.0005, 
Figure 5). Regions that strayed from this trend were 2, 4, and 10.  
The dominant subtype of influenza virus circulating at the peak of the outbreak has an 
effect on the timing of the epidemic peak (p=0.0396, Figure 6). Subtype H1 was heavily 
concentrated in February (66.67%) with little spread in other months, subtype H3 had the most 
peaks in February (38.6%) but had more peaks occur in earlier months (December and January), 
and the H1N1 subtype from the 2009 pandemic had the majority of its peaks (60.0%) in January 
(Table 6). Similarly, the median peak week of the 2009 H1N1 subtype occurred 3.5 weeks earlier 
than the median peak week of the H1 subtype (p=0.0337, Figure 7). 
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While peak size appears to vary depending on the dominant subtype circulating, the 
differences in median peak size across subtypes were not significant (p=0.1984, Figure 8).  
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Discussion 
Timing of Seasonal Influenza Peaks 
 The median peak week (week in which the highest incidence of ILI total occurred) across 
all of the HHS regions decreased significantly as the season increased (Figure 2), which indicates 
that seasonal flu epidemics have been peaking earlier over time. There is a lack of studies 
regarding temporality of seasonal flu epidemics in the United States, so anticipating earlier 
seasonal flu epidemics can be beneficial for earlier vaccination recommendations and 
preparation efforts. When seasonal flu epidemics occur, a strain is put on healthcare services, so 
insight on the timing of the seasonal peak could allow them to prepare adequately. Also, since 
vaccines provide protection for around six months, early flu vaccination should be recommended 
as the highest rates of ILI (peak) are being seen earlier in the season [10].  
 The timing of the seasonal flu peak (median peak week) did not vary significantly across 
HHS regions [Figure 3]. Ranging from week 18-21 of the flu season, the temporal spread of ILI 
peaks was small across the regions. A study of the 2009 H1N1 pandemic in Chile revealed a 
latitudinal gradient in which a temporal lag was seen from South to North [19]. This lag/gradient 
was not seen observed in the U.S, though this may be due to the regions in Chile having a greater 
difference in climactic conditions compared to the U.S. regions. Also since only median peak 
week was assessed, further comparison of peak week across regions by year may reveal a 
significant pattern.  
 The analysis revealed that timing of the seasonal flu peak is affected by the dominant 
subtype (Type A) circulating. Subtype H1-dominant peaks occurred most often in February 
(66.67%), and the 2009 H1N1 subtype occurred most often in January (60.00%). Subtype H3 
was spread more evenly across peak months, but had the highest frequency in February [Table 
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6]. Dunn’s test showed a significant difference of 3.5 weeks in median peak timing between 
subtypes H1 (Week 20.5) and 2009 H1N1 (Week 17) [Figure 7]. These results are again 
important for preparation and vaccination strategies. In seasons where the 2009 H1N1 strain is 
circulating, an earlier epidemic peak may be expected.  
 
Size of Seasonal Influenza Peaks 
 The size of seasonal flu epidemic peaks (maximum ILI total per flu season) is increasing 
over time. The majority of HHS regions (Regions 2, 3, 5, 6, 8, and 10) showed a strong 
correlation of increasing size over time (Figure 4); when assessed across all regions, a weak 
positive correlation was observed despite regional variation. The increase of ILI total over time 
does not necessarily indicate that the burden of influenza is increasing over time. Since the U.S. 
population, more specifically the population with access to healthcare, was increasing over this 
time period (2005-2015), the higher ILI totals may not be representative of the change in burden 
over time. However, the increasing size in peaks still represents the importance of universal 
vaccination coverage, as recommended by the CDC [10].  
 Based on this analysis, the dominant subtype circulating did not have an effect on the size 
of the seasonal epidemic peak, as the median peak size did not vary significantly across subtype 
(Figure 8). A study assessing seasonal flu characteristics by subtype in France found that seasons 
with subtype H3 dominating had higher incidence peaks [20]. The study in France, however, 
only compared subtypes H1 and H3 and did not include the 2009 H1N1 strain. The lack of 
significance in the Kruskal-Wallis test may be due to small sample sizes within subtypes (H1: 
18, 2009 H1N1: 15). 
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 The Spearman correlation coefficient between peak size and peak week (across all 
regions) indicates that there is a weak, but significant negative correlation between the two 
(Figure 5). As the peak week decreases, or occurs earlier in the year, the size of the epidemic 
peak increases. The median peak week was also found to differ significantly by peak month 
[Figure 9]. Dunn’s test lacks statistical power, and thus did not provide additional information on 
which month pairs varied significantly by size, but it can be seen that as month goes from 
December to March (excluding the one peak in April), the median peak size and IQR are 
decreasing by month (Figure 9). These results indicate that flu seasons with earlier epidemic 
peaks will be more intense (larger), which continues to confirm the importance of vaccination 
early in the season.  
 
Limitations 
 The use of ILI data as an indicator for rates of influenza activity may over or 
underestimate the actual burden per region. Overestimation could be due to the general clinical 
definition of influenza that may encompass other respiratory diseases; however, the clinical 
specification of “no other known cause other than influenza” may help reduce this 
overestimation [17]. ILI data could also underestimate the burden of influenza, as the data only 
includes those who sought healthcare for their symptoms.  
For this analysis, only the peak size (maximum ILI total) was recorded per season, per 
region, and the peak size may not be representative of the size of the season as a whole. 
However, since this study was focused on peak characteristics, the ILI total was sufficient as an 
indicator of size and timing of seasonal flu peaks. 
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The dominant subtype was only recorded at the peak week, and so may not be an 
accurate representation of the primary subtype circulating throughout the season. Also, not all 
positive influenza samples are subtyped. Future research assessing subtype prevalence 
throughout the flu season would be beneficial for determining the effect it has on characteristics 
of the season.  
 Sample sizes within regions were small (N=9), so statistical power was lacking for 
analysis within regions. Also, the use of nonparametric statistical tests (Kruskal-Wallis, Dunn’s 
test, Spearman’s rho) decreases the statistical power and contributes to a lack of significant 
results. Future studies analyzing trends over a greater period of time, or over various points of a 
season, may provide more significant results.  
 
Conclusion 
 While the U.S. has a comprehensive surveillance system, and the CDC publishes weekly 
updates on the outlook of seasonal influenza activity (FluView), there is a lack of literature 
analyzing seasonal influenza peak trends across and within regions of the country over multiple 
flu seasons. In this study, a significant decrease in peak week and a significant increase in peak 
size were observed over time, revealing a trend of earlier and more intense seasonal flu peaks. 
While subtype did not have an effect on the size of the epidemic peak, the median peak week 
varied based on the dominant circulating subtype. Trends in seasonal epidemic peak 
characteristics have important implications for predictive techniques, vaccination 
recommendations, and prevention strategies: trends of earlier and more intense epidemics should 
result in encouraging vaccination and personal protection methods earlier in the flu season. 
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Figures 
 
Figure 1. Health and Human Services Regions [21] 
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Figure 2. Peak week over time (by year) per HHS Region (p<0.0001) 
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Figure 3. Peak timing (week) by Health and Human Services Region (p=0.8541) 
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Figure 4. Maximum ILI total (peak size) over time (year) per HHS region (p=0.012) 
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Figure 5. Correlation of peak size by peak week (p=0.0005) 
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Figure 6. Month in which the peak of the outbreak occurs by dominant subtype circulating 
(p=0.0396) 
 
 
 
 
 
Figure 7. Peak timing (week, y-axis) by dominant subtype circulating (p=0.0337).  
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Figure 8. Peak influenza-like illness total (y-axis) by dominant subtype circulating 
(p=0.1984) 
 
 
 
 
 
 
Figure 9. Peak influenza-like illness total (y-axis) by month in which the peak occurs 
(p=0.0494) 
 
